TRaaS On Product
6696
Axel Mark
3624
Wintest
6721
GMO AD Partners
4784
General Oyster
3224
日本市場個股詳情
7775 大研醫器
- 505
- -1-0.20%
延時20分鐘行情午間休市 12/25 11:09 (東京)
160.79億總市值14.68市盈率(靜)
507最高價503最低價1.40萬股成交量503今開506昨收704.73萬成交額58652周最高0.11%換手率3184.00萬總股本45252周最低36.88每股收益TTM65.55億流通值1417歷史最高14.68市盈率(靜)1298.01萬流通股134歷史最低34.41每股收益(静)0.79%振幅21.00股息TTM1.99市淨率100股每手4.16%股息率TTM
大研醫器關鍵統計數據
季報+年報
顯示同比
| (FY)2024/03/31 | (Q4)2024/03/31 | (Q3)2023/12/31 | (Q2)2023/09/30 | (Q1)2023/06/30 | (FY)2023/03/31 | (Q4)2023/03/31 | (Q3)2022/12/31 | (Q2)2022/09/30 | (Q1)2022/06/30 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 營業總收入 | 6.71%97.5億 | 4.60%23.44億 | 5.74%25.82億 | 9.05%24.63億 | 7.53%23.62億 | 6.99%91.37億 | 5.70%22.41億 | 4.59%24.42億 | 7.08%22.58億 | 11.09%21.96億 |
| 主營業務成本 | 2.88%57.68億 | -7.21%14.4億 | 3.80%14.97億 | 7.25%14.27億 | 9.50%14.04億 | 15.45%56.07億 | 21.44%15.51億 | 10.07%14.43億 | 14.79%13.31億 | 15.60%12.82億 |
| 毛利 | 12.80%39.82億 | 31.17%9.04億 | 8.54%10.84億 | 11.64%10.35億 | 4.78%9.58億 | -4.17%35.3億 | -18.17%6.9億 | -2.42%9.99億 | -2.33%9.27億 | 5.33%9.14億 |
| 營業費用 | 2.57%25.39億 | 15.61%6.99億 | -6.64%5.92億 | 3.08%6.29億 | -1.19%6.19億 | -2.27%24.76億 | -3.29%6.05億 | -3.23%6.34億 | -3.61%6.1億 | 1.17%6.26億 |
| 營業利潤 | 36.81%14.43億 | 142.25%2.05億 | 34.93%4.92億 | 28.12%4.06億 | 17.76%3.39億 | -8.38%10.54億 | -61.00%8,470.8萬 | -0.98%3.65億 | 0.22%3.17億 | 15.66%2.88億 |
| 營業外利息收入與支出淨額 | -21.69%-482.5萬 | -15.60%-120.8萬 | -27.50%-121萬 | -21.05%-120.2萬 | -23.21%-120.5萬 | -6.10%-396.5萬 | -20.67%-104.5萬 | -4.40%-94.9萬 | 0.90%-99.3萬 | -1.88%-97.8萬 |
| 營業外利息收入 | --0 | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| 營業外利息支出 | 21.69%482.5萬 | 15.60%120.8萬 | 27.50%121萬 | 21.05%120.2萬 | 23.21%120.5萬 | 6.10%396.5萬 | 20.67%104.5萬 | 4.40%94.9萬 | -0.90%99.3萬 | 1.88%97.8萬 |
| 投資淨收益 | 526.72%290.8萬 | 3,000.00%86.8萬 | 29.45%-19.4萬 | -6.06%9.3萬 | 249.84%214.1萬 | -60.14%46.4萬 | -97.15%2.8萬 | -759.38%-27.5萬 | 201.02%9.9萬 | 96.78%61.2萬 |
| 被指定為現金流套期的金融工具損益 | ||||||||||
| 終止確認可供出售金融資產損益 | ||||||||||
| 聯營企業及其他參股權益產生的收益 | ||||||||||
| 特殊收入（費用） | 60.90%-1,118.5萬 | 71.16%-825.7萬 | -6,936.49%-505.9萬 | 4,414.00%215.7萬 | -2.6萬 | -2,658.82%-2,860.9萬 | -20,953.68%-2,863.3萬 | 135.24%7.4萬 | 87.28%-5萬 | 0 |
| 減：其他特殊費用 | -60.90%1,118.5萬 | -71.16%825.7萬 | 6,936.49%505.9萬 | ---215.7萬 | --2.6萬 | 2,658.82%2,860.9萬 | 20,953.68%2,863.3萬 | -135.24%-7.4萬 | ---- | ---- |
| 其他營業外收入（費用） | 158.71%691.8萬 | 79.89%200.4萬 | 589.49%203.4萬 | 37.74%108.4萬 | 275.73%179.6萬 | -34.27%267.4萬 | -20.14%111.4萬 | -67.29%29.5萬 | 29.65%78.7萬 | -58.93%47.8萬 |
| 稅前利潤 | 40.14%14.36億 | 253.60%1.99億 | 34.03%4.88億 | 28.86%4.08億 | 18.66%3.42億 | -10.97%10.25億 | -74.30%5,617萬 | -1.14%3.64億 | 0.45%3.17億 | 15.60%2.88億 |
| 所得稅 | 43.10%4.48億 | 204.56%9,816.8萬 | 30.63%1.37億 | 28.34%1.15億 | 13.18%9,711萬 | -2.28%3.13億 | -35.09%3,223.3萬 | -1.11%1.05億 | -1.72%8,989.4萬 | 17.63%8,580萬 |
| 除稅後利潤 | 38.84%9.89億 | 319.65%1億 | 35.40%3.5億 | 29.06%2.93億 | 20.98%2.45億 | -14.32%7.12億 | -85.83%2,393.6萬 | -1.16%2.59億 | 1.34%2.27億 | 14.76%2.02億 |
| 持續經營利潤 | 38.84%9.89億 | 319.63%1億 | 35.40%3.5億 | 29.06%2.93億 | 20.98%2.45億 | -14.32%7.12億 | -85.83%2,393.7萬 | -1.16%2.59億 | 1.34%2.27億 | 14.76%2.02億 |
| 歸屬于少數股東的淨利潤 | ||||||||||
| 歸屬於母公司的淨利潤 | 38.84%9.89億 | 319.65%1億 | 35.40%3.5億 | 29.06%2.93億 | 20.98%2.45億 | -14.32%7.12億 | -85.83%2,393.6萬 | -1.16%2.59億 | 1.34%2.27億 | 14.76%2.02億 |
| 優先股派息 | ||||||||||
| 其他優先股派息 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 歸屬于普通股股東的淨利潤 | 38.84%9.89億 | 319.65%1億 | 35.40%3.5億 | 29.06%2.93億 | 20.98%2.45億 | -14.32%7.12億 | -85.83%2,393.6萬 | -1.16%2.59億 | 1.34%2.27億 | 14.76%2.02億 |
| 總派息金額 | ||||||||||
| 基本每股收益 | 38.81%34.41 | 315.48%3.49 | 35.41%12.2 | 29.11%10.2 | 21.02%8.52 | -14.31%24.79 | -85.71%0.84 | -1.21%9.01 | 1.41%7.9 | 14.66%7.04 |
| 稀釋每股收益 | 38.81%34.41 | 318.88%3.49 | 35.40%12.1997 | 29.06%10.1958 | 21.02%8.52 | -14.31%24.79 | -85.83%0.8332 | -1.16%9.01 | 1.41%7.9 | 14.66%7.04 |
| 每股派息 | 5.00%21 | 9.09%12 | 0 | 0.00%9 | 0 | 0.00%20 | 0.00%11 | 0 | 0.00%9 | 0 |
| 貨幣單位 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 |
| 會計準則 | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |